|
| Biomarker | Cancer type (subtype) | Companion diagnostics (company) | Drug therapy (company) | Reference |
|
| HER2 (gene amplification) | Breast cancer (HER 2 positive) |
**SPoT-Light HER2 CISH **Hercep test (Life Technologies, NY) |
**Herceptin, trastuzumab (Hoffman La Roche Inc.) | [13, 14] |
|
| ALK (chromosome rearrangement) | Nonsmall cell lung cancer (anaplastic lymphoma kinase (ALK) positive advanced nonsmall cell lung cancer) |
**Vysis ALK FISH test (Abbott Laboratories, Abbott, IL) |
**Xalkori, crizotinib (Pfizer) | [13, 15] |
|
| EGFR KRAS (mutation) | Colorectal Cancer (expressing metastatic colorectal carcinoma, EGFR) |
**Therascreen KRAS Test (Qiagen, Corporate Headquarters, Nederland’s) |
**Erbitux, cetuximab (ImClone, ImClone Systems, NJ) **Vectibix, panitumumab (Amgen, Amgen Inc,. CA) | [13, 16, 17] |
|
| BRAF V600E (mutation) | Melanoma (metastatic melanoma with BRAFV600E mutation) |
**Cobas 4800 BRAF V600 Mutation Test (Panagene, Corporate Headquarters, Korea) |
**Zelboraf, vemurafenib (Genentech/Roche) | [13, 18] |
|
| BRCA1/2 (gene translocation) | Breast cancer (median, triple-negative, HER2+, and ER+/HER2−) | N/A |
*Veliparib, ABT-888 (Abbott)
*Olaparib, AZD2281 (Abbott) | [13, 19, 20] |
|
| PML-RAR (gene translocation) | Acute Promyelocytic Leukemia | N/A |
**Trisenox, arsenic trioxide (Teva, Israel) | [13, 23] |
|
| BCR-ABL (gene translocation) | Chronic myelogenous leukemia | N/A |
**Gleevec, imatinib (Novartis)
**Sprycel, dasatinib (Bristol Myers Squibb)
**Tasigna, nilotinib (Novartis) | [13, 24, 25] |
|
| C kit, FIP1L1-PDGFRα | Chronic myeloid leukemia (Ph+ CML) gastrointestinal stromal tumor (GIST) |
**DAKO C-KIT PharmDx |
**Dako North America, Inc. | [26] |
|
| CD 20 | Non-Hodgkins lymphoma (CD20+ follicular B-cell non-Hodgkin’s lymphoma) |
*Rituxan Sensitivity (CD20), Flow cytometry assay |
**Bexxar, tositumomab (GlaxoSmithKine) | [27] |
|
| CD 25 | T-cell lymphoma (cutaneous T-cell lymphoma,) |
*ONTAK Sensitivity (CD25), Flow Cytometry (Quest Diagnostics) |
**Ontak, denileukin diftitox (Marathon Biopharmaceuticals Inc. MA) | [28] |
|
| CD 30 | Refractory Hodgkins lymphoma |
*Fluorescent microsphere immunoassay, (Quest Diagnostics) |
**Adcetris, brentuximab vedotin (Seattle genetics Inc.) Corporate Headquarters, Seattle Genetics, Inc., WA, USA. | [29] |
|
| TPMT | (CD30+ lymphoma) |
*TPMT Activity, Liquid Chromatography Tandem Mass Spectrometry (LC/MS/MS) (Quest Diagnostics) |
**Tabloid, thioguanine (GlaxoSmithKine) | [30] |
|
| DPD | Breast cancer (with TS, MTHFR, and DPD gene polymorphisms) |
*Polymerase Chain Reaction (PCR) Single Nucleotide Primer Extension |
**Xeloda, capecitabine (Hoffman La Roche Inc.) | [31] |
|
| ER-PGR | Breast cancer (ER and/or PGR+) |
*Immunohistochemistry (IHC) (Quest Diagnostics) |
**Aromasin, exemestane (Pfizer) | [32] |
|
| G6PD | Lymphoma, leukemia (lymphoid leukemia (B and T cell), non-Hodgkin’s lymphoma (including Burkitt’s lymphoma) or acute myelogenous leukemia) | N/A |
**Elitek, rasburicase (Sanofi-synthelabo Inc.) | [33] |
|
| ER | Breast cancer (low-grade ER−/PR+) |
*Immunohistochemical Assay (Quest Diagnostics) |
*Nolvadex, tamoxifen (AstraZeneca) | [34] |
|
| ER | Breast cancer (ER+) | N/A |
*Arimidex, anastrozole (AstraZeneca) | [35] |
|
| ER | Breast cancer (ER+ and/or PgR+) | N/A |
**Faslodex, fulvestrant (AstraZeneca) | [36] |
|
| UGT1A1 | Colorectal cancer (UGT1A1*28 polymorphisms) |
*Fluorescent polymerase chain reaction (PCR) with primers specific for the 5′ untranslated region of UGT1A1 (Third Wave Technologies, WI) |
**Camptosar, irinotecan (Pfizer) | [37] |
|
| ERCC1 | Gastrooesophageal cancer (with ERCC1 nuclear protein expression) | N/A |
*Camptosar, irinotecan (Pfizer) | [38] |
|
| TPMT | Metastatic Testicular tumors
Metastatic ovarian tumors
Advanced bladder cancer | N/A |
*Platinol, cisplatin, (Bristol-Myers Squibb Company) | [39] |
|
| TPMT | Acute nonlymphocytic leukemias | N/A |
**Tabloid, thioguanine (GlaxoSmithKline) | [40] |
|
| CDK 4 and 6 | Breast cancer (luminal estrogen receptor-ER+, HER2−) | N/A |
*Palbociclib, PD-0332991 (Pfizer) | [41] |
|
